### **Poster sessions**

both heard and empowered and felt all the information they offered was precious.

Discussion Patients found it a powerful experience and felt they made a contribution for the future. Professionals gained emotional and practical insights which inspired motivation for change in service delivery. The process tapped into strong motivations for mutual understanding. It is an effective element in developing person-centred COPD services and is transferable to other LTCs.

Supported by grant from the Health Foundation

P94

# PATIENT AGENDA SETTING AND CLINIC EFFICIENCY IN OUTPATIENTS: AN INDIVIDUAL RANDOMISED CONTROLLED TRIAL

A Everden, F Early, K Homan, J Fuld. Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK

10.1136/thoraxjnl-2014-206260.235

Introduction Most patients have issues to raise in a consultation but may not actually raise them, adversely affecting the consultation outcome. Evidence suggests that methods to help patients consider their information needs before a consultation can increase satisfaction without increasing consultation length but there is a need to assess a wider range of outcome measures and to measure consultation length accurately.

We studied the impact of a paper agenda form to prompt question asking in a respiratory outpatient clinic. The primary objective was to identify whether this increased agreement that "My doctor discussed the issues that were important to me". Secondary endpoints included consultation length and post-consultation confidence to self-manage (0–10 scale).

Method Patients were randomised to receive the agenda form or usual care by blocked randomization (block size 6), stratified by consultant. Patients receiving the form had a written brief inviting them to complete it in the waiting room.

PROMs were collected post-consultation. Consultations were timed by an observer outside the room. As planned in the protocol, categorical data were analysed using Fisher's exact test and continuous data were analysed using a t-test. Exploratory

Abstract P94 Table 1 Analysis of primary and secondary outcomes measures

My doctor discussed the issues	SD*	Agenda form N=83 1 (1.2%)	Usual care N=80	P-value
that were important to me	A SA	17 (20.5%) 63 (75.9%)	21 (26.3%) 56 (70.0%)	0.4567
I raised with my doctor the issues that were important to me	SD A SA	1 (1.2%) 21 (25.3%) 57 (68.7%)	18 (22.5%) 59 (73.8%)	0.6464
got the outcome I wanted from my consultation	SD D A SA	1 (1.2%) 2 (2.4%) 18 (21.7%) 58 (69.9%)	2 (2.5%) 24 (30.0%) 50 (62.5%)	0.4591
How confident do you feel that you can take steps to manage your condition as a result of today's visit? (0-10)	n Mean (SD) Median Min, Max	79 8.7 (1.92) 10 3, 10	73 8.7 (1.34) 9 5, 10	0.795
Consultation duration (mins)	n Mean (SD) Median Min, Max	83 15.2 (7.69) 13 3, 40	78 15.3 (7.98) 14.8 2. 44	0.908
*SD (Strongly Disagree) D (Disagree) A (Agree) SA (Strongly Agree)	,	5, 10	<b>-,</b> · ·	

analyses to assess the effects of a number of factors used mixed model ANOVA.

Results Groups were well matched at baseline for age, gender and respiratory diagnosis. There was no significant effect of agenda form use on the primary or secondary endpoints (Table 1). Exploratory analyses identified that in new patients (but not in follow-up patients) the form was associated with shorter consultation length (LS mean=15.2 mins) than usual care (LS mean=21.3 mins) (p = 0.017) and with lower confidence to self-manage (LS mean=6.6) than usual care (LS mean=9.2) (p = 0.001).

Conclusion There was no overall benefit from the form and a risk of detrimental impact on patient experience for some patients. This resonates with reports from other more complex self-management interventions that have found unexpected detrimental effects in some patients. There is a need for greater understanding of what works for whom with regard to self-management support. It cannot be assumed that the impact will be universally beneficial at best or neutral at worst.

#### REFERENCE

1 Trial reference: REC reference: 13/WA/0171

P95

#### NON CF BRONCHIECTASIS


CJ Baggott, E Harris, J Suntharalingam, AS Malin. Royal United Hospitals Bath, Bath, UK

10.1136/thoraxjnl-2014-206260.236

Background Bronchiectasis is said to affect 100/100 000, however the true prevalence is probably significantly higher. Our previous BTS bronchiectasis audit identified that a significant service improvement was required. This led to the introduction of a home intravenous antibiotic pilot, a bronchiectasis working group, and enhanced teaching and information sharing with primary care. Despite this, these patients remain poorly served both in the community and hospital.

From 2009–13 there were 330 bronchiectasis admissions to our hospital. A significant proportion of these could have been managed in the community, substantially reducing the cost to the NHS. Aims We are developing an integrated bronchiectasis service between hospital and community. The vision has been to create a primary and secondary care interface, utilising the usual multi-disciplinary team plus psychology and dietetic support, a 'hospital without walls' model and an online, multi-faceted communication tool.

### Integrated bronchiectasis care pathway



Abstract P95 Figure 1

A118 Thorax 2014;**69**(Suppl 2):A1–A233

Outputs We provided *Pseudomonas* eradication therapy (previously published – White *et al.* 2012) and have piloted a home intravenous antibiotic service providing treatment for exacerbations which saved 497 hospital bed days in 2013. Twenty one patients received 37 home intravenous courses; of these, 17 courses were self-administered. Overall we reduced annual bronchiectasis admissions by 30% when comparing with 2011–12, equivalent to 23 fewer admissions over the year.

We have developed an online database and clinical record tool which can be shared and updated by hospital and community alike. As well as allowing rapid communication, the database shows trend analysis, logging of microbiology/antibiotic use and is a valuable audit and research resource.

We held a recent workshop comprising CCG, community partners and hospital stakeholders. We developed a new dynamic care pathway showing a combined "community/hospital hub" which will work with partners in primary and secondary care (Figure 1). We propose that such shared care working represents a useful model for broad application elsewhere.

## Getting to grips with paediatric lung disease

P96

A NEW INTERACTIVE GAME DEVICE MAY IMPROVE COMPLIANCE WITH SPACER DEVICES IN VERY YOUNG CHILDREN

<sup>1</sup>CS Murray, <sup>2</sup>S Shakir, <sup>1</sup>T Aslam. <sup>1</sup>University of Manchester and Central Manchester University Hospitals NHS Foundation Trust , Manchester, UK; <sup>2</sup>Penine Acute Hospitals NHS Trust, Manchester, UK

10.1136/thoraxjnl-2014-206260.237

Background The use of spacers in young children is not always easy and can result in distressed children and parents. We aimed to develop and assess an interactive electronic game to improve ease of use and potentially compliance with inhalers in young children.

Methods The Respiratory Aid For Inhalers (RAFIhaler) consists of an electronic sensor adjacent to the outflow valve of a spacer mask, providing input every 0.1 seconds to a custom designed android application on a smartphone that is mounted, in full view of the child, on top of the spacer. The application displays on-screen characters designed to respond to correct breathing as part of a game storyline, for example by blowing away characters unfriendly to the hero (RAFI) or blowing his boat across a river. The RAFIhaler was developed through iterative testing and multiple redesigns of hardware and software until a satisfactory final module was completed.

This module was tested on 14 children admitted to hospital with acute wheeze by an independent researcher, along with a survey to assess the child's reaction and the parent and child's perceived benefit from RAFIhaler. Open-ended questions allowed further feedback.

Results Fourteen children (2–7 yrs, 7M:7F) participated; 13 children and 14 parents completed the survey. All children stated they enjoyed the activity. Eleven children responded further; 10 (91%) felt the RAFIhaler helped them taking medication. All but one parent felt that RAFIhaler helped their child use the spacer. Of the thirteen parents who felt the RAFIhaler helped, three felt their child previously really struggled with the inhaler. Some benefits of RAFIhaler voiced by parents were: enjoyable (3); good distraction (3); made child calmer (2); helped in breathing/

inhalation technique (3); would be useful at home (1). One parent felt RAFIhaler was not of benefit as they felt their child already took their inhaler well.

Conclusions Children universally found using the RAFIhaler with their spacer enjoyable. The majority of parents felt the RAFIhaler helped their child take their medicine. The RAFIhaler may be of use both in encouraging young children to use their inhaler/spacer, and in combatting anxiety and stress associated with their use.

P97

# DIVERGING TRENDS IN PREVALENCES OF ASTHMA, ECZEMA AND HAYFEVER IN CHILDREN AGED 9–12 YEARS

M Barnish, N Tagiyeva, L Aucott, G Devereux, S Turner. *University of Aberdeen, Aberdeen,* 


10.1136/thoraxjnl-2014-206260.238

Introduction The prevalences of childhood asthma, eczema and hayfever have been recorded in our local population since 1964. The prevalence of a lifetime history of asthma rose from 4% in 1964 to a peak of 28% in 2004 before falling back to 22% in 2009. Wheeze in the past 12 months fell from 19% in 2004 to 16% in 2009. Lifetime prevalences of eczema and hay fever were approximately 5% in 1964 and had risen to 30% and 25% in 2004 and 2009. Here we present the results of our 2014 survey where we tested the hypothesis that eczema and hayfever prevalence will have followed the earlier trend for asthma and fallen since 2009.

**Methods** Children aged 9 to 12 years attending local primary schools were eligible. The questionnaire used in previous surveys was distributed to children by teaching staff, completed by parents at home and returned directly to the researchers.

Results Forty-seven schools were invited to participate of whom 41 took part. There were 4175 questionnaires distributed and 1378 returned (33%). The mean (SD) age was 10.9 (1.1) and 50% were boys. A lifetime history of asthma was reported in 17%. Lifetime prevalences of eczema and hay fever were 31% and 30% respectively. Wheeze in the past 12 months was reported in 13%.

Conclusions The proportion of children with a history of ever having had asthma and of recent wheeze continues to fall in our population at a time when the prevalences of eczema and



Abstract P97 Figure 1

Thorax 2014;**69**(suppl 2):A1–A233